Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 25, 2025
Product Development

Indication selection: Lessons learned from the CRISPR-Cas9 story

Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned
BioCentury | Feb 18, 2025
Product Development

Remaking Roche

How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Mar 1, 2024
Product Development

Rare disease spotlight: enzyme replacement therapy for the brain

At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA
BioCentury | Sep 18, 2023
Product Development

Data comp: four hypertension candidates advancing in the clinic

Idorsia’s aprocitentan under review, while Mineralys and AZ prepare for Phase III trials and Alnylam runs two more Phase II studies
BioCentury | Jul 24, 2023
Deals

Alnylam continues shift to common diseases, with Roche as hypertension partner

Pharma pays $310M up front to share rights to RNAi therapy; betting on CVOT data, less frequent dosing to outcompete generics
Items per page:
1 - 10 of 76